Table 1 Correlation between WWP2 expression and clinicopathologic factors in ALL patients.

From: The role of E3 ubiquitin ligase WWP2 and the regulation of PARP1 by ubiquitinated degradation in acute lymphoblastic leukemia

Clinicopathologic Factors

Cases

WWP2 expression

P value

Gender

  

0.162

 Male

40

0.0731 ± 0.1059

 

 Female

27

0.1242 ± 0.1648

 

Age

  

0.154

 <42

33

0.0700 ± 0.1029

 

 ≥42

44

0.1166 ± 0.1567

 

FAB subtype

  

0.016*

 L1

5

0.0265 ± 0.0103

 

 L2

54

0.0767 ± 0.1076

 

 L3

8

0.2500 ± 0.2195

 

T/B subtype

  

0.458

 T cell

8

0.1491 ± 0.2235

 

 B cell

59

0.0861 ± 0.1180

 

Blast cell (Bone marrow smear)

  

0.493

 <32%

33

0.0822 ± 0.1392

 

 ≥32%

34

0.1048 ± 0.1299

 

Blast cell (Flow cytometry)

  

0.032*

 <32.8%

33

0.0583 ± 0.0984

 

 ≥32.8%

34

0.1279 ± 0.1551

 

WBC (*109/L)

  

0.980

 <5.03

34

0.0933 ± 0.1272

 

 ≥5.03

33

0.0941 ± 0.1427

 

Hb (g/L)

  

0.470

 <100

33

0.1058 ± 0.1236

 

 ≥100

34

0.0819 ± 0.1442

 

PLT (*109/L)

  

0.370

 <131

32

0.1091 ± 0.1349

 

 ≥131

35

0.0795 ± 0.1335

 

BCR/ABL appearance

  

0.586

 Positive

16

0.0780 ± 0.0940

 

 Negative

8

0.0531 ± 0.1273

 

Karyotype

  

0.645

 Normal

12

0.1827 ± 0.2074

 

 t (9;22)

4

0.1546 ± 0.1324

 

 Complex

4

0.1683 ± 0.1825

 

 Others

7

0.0828 ± 0.1111

 
  1. The significance of bold values is shown as follows: *p < 0.05; **p < 0.01.
  2. Data loss exists in BCR/ABL appearance and Karyotype analysis.